A Phase III Randomized, Double-blind, Placebo-controlled Study of LEE011 or Placebo in Combination With Tamoxifen and Goserelin or a Non-steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Ribociclib (Primary) ; Anastrozole; Goserelin; Letrozole; Tamoxifen
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms MONALEESA-7
- Sponsors Novartis; Novartis Pharmaceuticals
- 04 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Mar 2017 Status changed from active, no longer recruiting to recruiting.
- 03 Aug 2016 According to a Novartis media release, this trial is fully enrolled.